Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE) closed an upsized underwritten public offering on March 12, 2026, raising approximately $747.5 million in gross proceeds.

The company sold 12,236,843 common shares (including 1,710,526 shares from full exercise of the underwriters' option) and issued pre-funded warrants to purchase up to 877,194 common shares at $56.9999 each; each pre-funded warrant has an exercise price of $0.0001.

Positive

• $747.5M gross proceeds raised in the offering
• Full exercise of the underwriters’ option (1,710,526 shares)
• Pre-funded warrants issued for 877,194 potential shares

Negative

• Issued 12,236,843 new common shares, creating shareholder dilution

News Market Reaction – XENE

-4.61%

-4.61% Session close to close

In the Mar 13 session, XENE declined 4.61%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms the closing of Xenon’s upsized underwritten offering, raising gross proce...

Analysis

This announcement confirms the closing of Xenon’s upsized underwritten offering, raising gross proceeds of $747.5M through 12,236,843 common shares and 877,194 pre-funded warrants priced at $57.00. It follows a sequence of proposed and priced offerings earlier in March. Historically, similar financing steps produced modest share pressure, underscoring investor focus on dilution. Monitoring subsequent pipeline milestones and capital deployment will be important alongside this enlarged cash position.

Key Figures

Common shares offered: 12,236,843 shares Underwriters’ option shares: 1,710,526 shares Pre-funded warrants: 877,194 warrants +5 more

8 metrics

Common shares offered 12,236,843 shares Total common shares sold in the underwritten public offering

Underwriters’ option shares 1,710,526 shares Additional common shares sold via full exercise of underwriters’ option

Pre-funded warrants 877,194 warrants Pre-funded warrants to purchase common shares issued in the deal

Common share offering price $57.00 per share Public offering price for each common share in this transaction

Pre-funded warrant price $56.9999 per warrant Purchase price per pre-funded warrant in the offering

Warrant exercise price $0.0001 per share Exercise price for each pre-funded warrant into common shares

Aggregate gross proceeds $747.5 million Gross proceeds before underwriting discounts and expenses

Current share price $59.04 Price as of last close, post-pricing but before this closing news

Previous Offering Reports

2 past events · Latest: Mar 10 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	Offering pricing	Negative	-2.6%	Priced upsized $650M public offering including pre-funded warrants.
Mar 09	Offering proposal	Negative	-3.4%	Announced proposed $500M public share offering plus $75M underwriter option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent offering-related announcements have consistently coincided with single-day share price declines of around 3%, indicating a recurring dilution-sensitive reaction.

Recent Company History

Over recent weeks, Xenon combined major clinical and financing milestones. A positive Phase 3 X-TOLE2 readout on Mar 9, 2026 coincided with a 49.64% jump, followed immediately by a proposed and then upsized public offering, which saw declines of -3.43% and -2.59% on Mar 9 and Mar 10, respectively. Today’s closing of the upsized $747.5M offering extends that financing sequence and continues the pattern of modest pressure around equity raises.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement

3 terms

underwritten public offering financial

"announced the closing of its previously announced underwritten public offering of 12,236,843 common shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"and pre-funded warrants to purchase up to 877,194 common shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded warrants were offered at a price of $56.9999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $747.5 million.

J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair acted as joint book-running managers for the offering. Baird acted as lead manager for the offering.

An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2024. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC on March 11, 2025 and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720 or by emailing syndprospectus@stifel.com; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com; or William Blair & Company, L.L.C.,  Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

No securities were offered or sold, directly or indirectly, in Canada or to any resident of Canada.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K_V7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.

Investor Contact:
Tucker Kelly
Chief Financial Officer
Email: investors@xenon-pharma.com

Source: Xenon Pharmaceuticals Inc.

FAQ

How much did Xenon (XENE) raise in the March 12, 2026 public offering?

Xenon raised approximately $747.5 million in gross proceeds. According to the company, this amount is before underwriting discounts, commissions and other offering expenses payable by Xenon.

How many shares did Xenon (XENE) sell in the offering and what was the price?

Xenon sold 12,236,843 common shares at $57.00 per share. According to the company, that total includes 1,710,526 shares from the underwriters’ full option exercise.

What are the pre-funded warrants issued by Xenon (XENE) in the offering?

Xenon issued pre-funded warrants to purchase up to 877,194 common shares at $56.9999 each. According to the company, each pre-funded warrant carries an exercise price of $0.0001.

Who managed Xenon’s (XENE) March 12, 2026 public offering?

The offering was led by J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, William Blair, and Baird. According to the company, these firms acted as joint book-running managers and lead manager.

Will the offering proceeds reduce Xenon’s (XENE) outstanding cash needs?

The offering provides approximately $747.5 million in gross proceeds to Xenon. According to the company, net proceeds will be reduced by underwriting discounts, commissions and other offering expenses.